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Abstract
HLA-A2 protects from EBV+ classical Hodgkin lymphoma (cHL) in Western Europe, but it is unknown whether this protective
effect also exists in the Chinese population. We investigated the association of HLA-A2 and specific common and well
documented HLA-A2 subtypes with EBV stratified cHL patients (n=161) from the northern part of China. Quantitative-PCR
and sequence-based subtyping was performed to identify HLA-A2 positive samples and their subtypes. 67 (42%) of the cHL
patients were EBV+. There were no significant differences in percentages of HLA-A2 positivity between cHL and controls
(65% vs 66%) and between EBV+ and EBV2 cHL patients (70% vs 61%). The frequency distribution of HLA-A2 subtypes was
significantly different between EBV stratified cHL subgroups and controls. This difference was most striking for the HLA-
A*02:07 type with a frequency of 38% in EBV+ cHL, 8% in EBV2 cHL and 20% in controls. Significant differences were also
observed for the HLA-A*02:07, HLA-A2 (non-02:07) and the A2-negative typings between EBV+ cHL vs controls (p=0.028),
EBV2 cHL vs controls (p=0.045) and EBV+ vs EBV2 cHL cases (p=2610
25). In conclusion, HLA-A*02:07 is a predisposing
allele for EBV+ cHL and a protective allele for EBV2 cHL in the northern Chinese population.
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Introduction
Classical Hodgkin lymphoma (cHL) has a complex multi-
factorial etiology with both genetic and environmental factors
contributing significantly to its development [1,2]. Epstein-Barr
virus (EBV), a ubiquitous human gamma-herpes virus that infects
over 90% of the population worldwide, has been consistently
linked to the pathogenesis of a subset of cHL [1,3]. Epidemiolog-
ical data indicates a bimodal disease model with different
pathogenetic backgrounds for EBV+ and EBV2 cHL. Despite
its strong oncogenic potential, only a minority of EBV-infected
individuals develop EBV+ cHL [3], because of effective anti-viral
immune responses.
The incidence of EBV+ cHL is strikingly increased in im-
munocompromised patients [4] indicating the importance of an
effective immune system in controlling the EBV+ cell population.
The human leukocyte antigen (HLA) is a crucial component of
the human immune system and HLA class I restricted, CD8+
cytotoxic T-cell (CTL) responses are known to play a pivotal role
in the control of EBV infection [5]. In EBV+ cHL there is a
so-called latency type II expression of viral genes by the tumor cells
that is restricted to the two latent membrane protein antigens
(LMP1 and LMP2) and EBV nuclear antigen 1 (EBNA1). Induc-
tion of LMP/EBNA1-specific immune responses has been
successful in the context of appropriate HLA molecules [6–10].
Genetic association between HLA and cHL has been
investigated in the Dutch, British and Scandinavian population
and HLA-A2 has consistently been reported as a protective type
for developing EBV+ cHL, while HLA-A1 is considered a risk type
[11,12]. A tentative explanation for this association is the known
presence of multiple cytotoxic T cell epitopes for LMP2 derived
antigenic peptides restricted through HLA-A2, whereas HLA-A1
restricted epitopes to the latent EBV peptides have not been found
[7,13]. HLA-A2 has a high prevalence worldwide [14] and is one
of the most diverse allele families of the HLA-A locus consisting of
over 300 allelic variants (IMGT/HLA database v 3.3.0). These
alleles show a marked difference in the capacity of peptide binding
and presentation [15,16] even for alleles that differ by only one
amino acid in the peptide binding groove. For example,
presentation of EBV derived peptides by the HLA-A*02:01 allele
induces stronger immune responses as compared to other HLA-A2
alleles, including HLA-A*02:07 [8]. The distribution of these
HLA-A2 allelic variants differs widely by geography and ethnicity
[14]. In the Caucasian population, .90% of the HLA-A2 positive
individuals carry the HLA-A*02:01 allele, whereas in the Chinese
population there are multiple common and well-documented
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A*02:06, A*02:07 and A*02:10 [14,17]. Based on these marked
differences, it can be postulated that interracial variations
influence the host immune response and this may lead to different
HLA-A associations in different populations.
Consistent with the Dutch population, HLA class I cell surface
expression was observed in the tumor cells of the vast majority of
Chinese EBV+ cHL patients [18]. In this study, we determined the
HLA-A2 phenotype frequency in Chinese cHL patients as well as
in controls from the same geographic region. The CWD HLA-A2
allelic variants were determined by sequence-based typing (SBT).
Results
HLA-A2 carrier frequency
Analysis of the 21 FFPE tissue samples of cHL patients with
known HLA-A genotype revealed a clear separation between
individuals lacking HLA-A2 alleles and individuals heterozygous
or homozygous for the HLA-A2 type (Figure 1). The relative
expression values varied between 0.002 and 0.027 for negative
patients and between 0.63 and 4.26 for positive patients.
The HLA-A2 carrier frequency in the total cHL patient group
(104 out of 161, 65%) was similar to the control group (79 out of
119, 66%). In contrast to the Western population, no difference
was observed between the HLA-A2 frequency in EBV+ (47 out of
67, 70%) and EBV2 Chinese cHL patients (57 out of 94, 61%)
(Table S1). This might be due to differences in HLA-A2 allelic
variants in the Chinese compared to the Dutch and Caucasian
populations.
HLA-A*02:07 risk allele analysis
HLA-A2 subtyping failed in 5 cHL patients and 3 controls due
to inefficient amplification of both exons and/or poor sequencing
results. For part of the patients subtyping was based only on the
exon 3 sequence analyses, which did not allow discrimination
between all of the CWD alleles. SBT results of the 99 HLA-A2
positive cHL patients and the 76 positive controls are shown in
Table S2. The distribution of HLA-A2 subtypes in controls and
the total cHL patient group was similar. In EBV status defined
subgroups the allele frequency for HLA-A*02:07 showed marked
differences, i.e. higher in EBV+ cHL and lower in EBV2 cHL
patients. Analysis of the frequency distribution of HLA-A2
negative, HLA-A*02:07 positive and HLA-A2 (non A*02:07)
individuals revealed significant differences between controls and
EBV status defined subgroups of cHL patients and also between
the EBV+ and EBV2 cHL groups (Table 1).
The odds ratio (OR) for HLA-A*02:07 was significantly
increased in EBV+ cHL as compared to EBV2 cHL (OR=
6.34, 95% CI=2.33–17.28, p=0.0003). In comparison to controls
the OR of EBV+ cHL was 2.09 (95% CI=0.95–4.57, p=0.066)
and the OR for EBV2 cHL was 0.33 (CI 0.13–0.86, p=0.023) for
HLA-A*02:07. No differences were observed for EBV stratified
cHL subgroups in comparison to controls for the HLA-A2 (non
A*02:07) type (Figure 2).
Multivariate analysis revealed that both mixed cellularity
subtype and HLA-A*02:07 positivity were significantly associated
with positive EBV status. Age, sex and HLA-A*02:xx (non
A*02:07) were not significantly associated. In our analysis HLA-
A*0207 status remained significant even after adjusting for age, sex
and diagnosis.
Discussion
HLA-A2 has been identified as a protective type and HLA-A1
as a risk type for the development of EBV+ cHL in the Dutch,
British and Scandinavian population [11,12]. In this study, we
found no difference of the HLA-A2 carrier frequency between
EBV status defined cHL patient groups and controls from
Northern China. However, a more detailed typing of specific
CWD HLA-A2 alleles in the Chinese population revealed that
HLA-A*02:07 is a risk allele for EBV+ cHL, whereas this allele is
protective for EBV2 cHL.
Our approach, using combined analyses of HLA-A2 specific
qPCR and sequence-based typing of the CWD subtypes, was of
crucial importance for identification of risk and protective alleles in
the Chinese population. Moreover, this study illustrates the
importance of considering differences in HLA subtype prevalence
in ethnic groups in genetic association studies especially for
associations in the HLA region. Differences in HLA types might
also explain the striking differences in cHL incidence in different
racial groups with a nearly 6-fold difference between Western
Europe and East Asia with an incidence of 2.3 and 0.4 per 100,000
inhabitants per year respectively in 2008 (http://globocan.iarc.
fr/).
We observed similar HLA-A2 frequencies in EBV+ and EBV2
Chinese cHL patients, whereas suballele frequencies differed
significantly with an increased percentage of HLA-A*02:07 in
EBV+ patients and a reduced frequency in EBV2 cHL patients.
Multivariate analysis indicated that both histological subtype and
HLA-A*02:07 were significantly associated with EBV, whereas
age and sex were not. Thus, our data indicate that the association
of HLA-A*02:07 with EBV status defined subgroups remained
significant after adjusting for age, sex and subtype.
HLA-A*02:07 is almost exclusively present in the eastern Asian
population and is the second most common allele just after the
HLA-A*02:01 allele [14]. This is also true for the northern
Chinese population, while in southern China the HLA-A*02:07
allele frequency was reported to be even higher than the HLA-
Figure 1. Validation of the HLA-A2 specific primer set on DNA
samples isolated from FFPE tissue sections from individuals
with known HLA genotypes. A clear difference can be observed
between samples possessing two or one HLA-A2 allele(s) and those
without HLA-A2 alleles. Homo, homozygous; hetero, heterozygous, neg,
negative.
doi:10.1371/journal.pone.0031865.g001
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A*02:01 allele and the HLA-A*02:07 allele at the protein level is a
unique amino acid change (Y99 to C). The question arises if this
single amino acid difference can indeed make a difference between
a risk and a protective allele. It has been shown that the peptide
binding repertoire of HLA-A*02:07 is limited to a subset of the
peptides presented by HLA-A*02:01 [8,10,19,20] or includes a
distinct set of peptides that were not presented by other HLA-A2
alleles [16]. Khanna et al showed that LMP1 peptides induced a
cytotoxic T cell response against EBV-infected B cells in the
context of several HLA-A2 alleles, including HLA-A*02:01, HLA-
A*02:02, HLA-A*02:03, HLA-A*02:04 and HLA-A*02:06 [21].
Lee et al demonstrated a less effective response to LMP2 peptides
using cytotoxic T cells from individuals carrying HLA-A*02:07 as
compared to individuals carrying HLA-*02:01, HLA-A*02:06 or
HLA-A*02:09 [8].
In the Dutch, British and Scandinavian population HLA-A1
was shown to be a risk allele for developing EBV+ cHL [11,12].
This allele is fairly uncommon in the Chinese population and we
did not observe significant differences in HLA-A1 carrier
frequencies between controls and EBV stratified cHL patients
using an HLA-A1 specific qPCR approach (results not shown). On
the amino acid level there are many (n=33) differences between
the HLA-A*01:01 allele and the HLA-A*02:07 allele, including
Y99 (is C in HLA-A*01:01). Thus, both susceptibility alleles differ
largely, while the protective HLA-A*02:01 allele differs from
HLA-A*02:07 by only a single amino acid (Y99 to C) as discussed
above. It remains unclear what the functional overlap between the
two highly different HLA-A*01:01 and HLA-A*02:07 alleles is,
but the consensus is that both alleles are ineffective in the
production of an interferon-gamma response against LMP1 or
LMP2 peptides [7,8,13]. An explanation for the risk of developing
EBV+ cHL linked to the identified alleles might thus be found in
differential specificity of binding and presentation of antigenic
peptides.
The HLA-A*02:07 allele is also associated with an increased risk
of undifferentiated nasopharyngeal carcinoma (UNPC) in the
southern Chinese population [22]. UNPC is an EBV-associated
malignancy and has an identical latency type of infection as cHL
with an expression pattern that is restricted to LMP1, LMP2 and
EBNA1 [23]. In the Caucasian population in the US HLA-
A*02:01 was associated with a decreased risk for UNPC [24,25].
The associations are similar to our findings in cHL, although
HLA-A1 is not a known susceptibility type for developing UNPC
in the Chinese population. Combination of our data showing an
association specifically in the EBV+ subgroup to the findings in
UNPC makes it now possible to more firmly link the HLA-
A*02:07 association directly to the ineffectiveness of this allele to
present LMP1 and LMP2 derived antigenic peptides in UNPC.
An unexpected finding in our study was the significantly
decreased HLA-A*02:07 frequency in the EBV- cHL population
as compared to controls. In theory, this might be explained by
differences in the composition of the pool of endogenous (mutated)
proteins. Thus, HLA-A*02:07 might induce strong immune
responses against peptides that are non-EBV related and that are
predominantly present in EBV2 cHL. This effect should probably
take place early in disease pathogenesis, as HLA class I expression
by EBV2 cHL tumor cells is frequently downregulated in cHL
patients at the time of diagnosis, also in Chinese cHL cases [18].
In conclusion, our study reports for the first time that the HLA-
A*02:07 allele has a strong predisposing effect for EBV+ cHL in
the Chinese population, while this allele is protective for EBV2
cHL. Discrimination between subtypes of HLA-A2 was of central
importance for understanding the genetic association of HLA-A2
with EBV+ cHL. Differences in HLA subtype frequencies in
different populations provide a unique opportunity for further
understanding the influence of genetic heterogeneity in HLA and
its role in the pathogenesis of EBV+ cHL.
Table 1. HLA-A*02:07 carrier frequency in Chinese controls and cHL patients.
HLA type
Controls
N( % )
all cHL
N( % )
EBV+
cHL N (%)
Controls vs
EBV+ p-value
I
EBV2
cHL N (%)
Controls vs
EBV2 p-value
I
EBV+ vs
EBV2 p-
value
I
A*02:07 23 (19.8%) 31 (19.9%) 24 (37.5%) 0.028 7 (7.6%) 0.045 2610
25
A2 (non A*02:07) 53 (45.7%) 68 (43.6%) 20 (31.3%) 48 (52.2%)
A2 negative 40 (34.5%) 57 (36.5%) 20 (31.3%) 37 (40.2%)
Failure* 3 5 3 2
IChi-square test comparing A*02:07, A2 (non A*02:07) and A2 negative frequencies between groups as indicated. There were no significant differences between controls
and the total cHL group.
*The failures are A2 positive patients (in table S2) for whom the PCR for SBT failed due to poor quality DNA.
doi:10.1371/journal.pone.0031865.t001
Figure 2. Odds ratios for HLA-A*02:07 subgroups for all cHL
patients versus controls (black), EBV negative cHL patients
versus controls (dark grey, p=0.023), EBV positive cHL
patients versus controls (light grey, p=0.066) and EBV positive
versus EBV negative cHL patients (white, p=0.0003). The HLA-
A*02 negative individuals constitute the reference group. Bars indicate
the 99% confidence intervals.
doi:10.1371/journal.pone.0031865.g002
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Study Population
Formalin-fixed paraffin-embedded (FFPE) tissue blocks of
lymph node biopsies from 161 cHL patients obtained from 5
hospitals in northern China (Dept. of Pathology, Health Science
Center, Peking University; Dept. of Pathology, First Hospital of
Jilin University; Dept. of Pathology, Shougang Hospital, Peking
University; Dept. of Pathology, Beijing Air Army General
Hospital; Zhanye Regional Hospital, Gansu Province) were used
for this study. Results of the hematoxylin & eosin (H&E) staining,
reclassification according to the WHO classification of 2008 and
EBER in situ hybridization (ISH) have been published previously
[18]. 67 of the 161 cHL were positive for EBV (42%).
To minimize genetic variations we included a control group of
119 reactive lymph nodes with lymphoid reactive hyperplasia
(n=88) or Kikuchi disease (n=31) obtained during the same
period from the Dept. of Pathology, Health Science Center,
Peking University as a control group. All analysis were done with
and without the Kikuchi controls and revealed the same allele
frequencies.
FFPE tissue blocks of 21 cHL patients with known HLA
genotype were retrieved from the University Medical Center
Groningen (UMCG), the Netherlands. These samples were used
to optimize and validate the HLA-A2 specific quantitative (q)PCR
and included 6 A2-homozygotes, 7 A2-heterozygotes and 8 non-
A2 genotypes. All procedures were carried out according to
institutional ethical review board guidelines of the UMCG.
Research was conducted adhering to the Declaration of Helsinki
and according to Dutch regulations (http://www.federa.org/). All
tissue samples were anonymyzed before use.
DNA isolation
2,31 0mm tissue sections were incubated overnight at 55uCi n
242 mL of PK1 lysis buffer (10 mM Tris pH 8.0, 50 mM KCl,
2.5 mM MgCl2, 0.45% NP40, 0.45% Tween 20, 0.01% gelatin)
with 7.5 mL Proteinase K (20 mg/ml, Invitrogen). Proteinase K
was heat inactivated for 5 min at 100uC. The supernatant
containing the DNA was carefully transferred into a new tube.
DNA was quantified by nanodrop-1000 spectrophotometer and
diluted to a concentration of 5 and 10 ng/mL for the subsequent
PCR analysis.
HLA-A2 quantitative (q)PCR
qPCR assays were carried out on an ABI PRISM 7900HT
(Applied Biosystems) with SYBR-green in a 384-well microtiter
plate using primers specific for HLA-A2 (Table S3). As a control
for quality and quantity we used a primer set for the PTP4A1
gene. All reactions were performed in triplicate in a final reaction
volume of 20 ml consisting of 10 ml SYBRH Green PCR master
mix (Applied Biosystems), 2 ml (3 mM) of each primer and 5 ml
(5 ng/ml) DNA. Each sample was analyzed in triplicate, starting
with a 2-min AmpErase UNG activation step at 50uC and a 10-
min hot start at 95uC, followed by 45 cycles of denaturation at
95uC for 15 s and combined annealing/extension at 60uC for
1 min. A melting curve was generated (95uC for 15 s, 60uC for
15 s, and 95uC for 15 s) to verify specificity of the PCR products.
Cycle threshold (Ct) values were determined by using the default
baseline setting of 3 to 15 cycles. All data were analyzed by using
ABI PRISM 7900 HT Sequence Detector Systems software
version 2.3 (Applied Biosystems). Samples with poor DNA quality
were excluded based on lack of a specific peak in the melting curve
or a Ct value higher than 36 for PTP4A1 (5 controls and 24
patients were excluded). HLA-A2 Ct values were normalized
against the Ct value for PTP4A1, resulting in a delta Ct. Relative
abundance of HLA-A2 was calculated by using the formula 2
2DCt.
Based on the 21 previously HLA-A typed samples, the cut-off level
for HLA-A2 positivity was set at a 2
2DCt value of 0.1. A 2
2DCt
value of 0.05 or less was considered to indicate absence of HLA-
A2.
HLA-A2 subtypes
Subtyping of HLA-A2 positive individuals was performed by
amplification and sequence analysis of exon 2 and exon 3 regions that
contain a number of SNPs that discriminate between the common
and well-documented (CWD) allelic variants in the Chinese
population (Table 1, Figure S1). DNA samples were amplified in a
volume of 25 mlc o n t a i n i n g5ml( 1 0n g / ml) DNA, 5 ml( 2m M )o f
each primer, 1.25 ml dNTPs (Invitrogen), 2.5 ml1 0 6reaction buffer
(Invitrogen), 5.85 mlH 2Oa n d0 . 4ml Taq Polymerase (Invitrogen).
Amplification was performed in a GeneAmp PCR System 9700
thermocycler (Applied Biosystems) with an initial 3-min hold at 95uC
and 40 cycles of 15 s at 95uC, 30 s at 65uC, and 1 min at 68uC,
followed by a final 10 min extension step at 68uC. PCR products
were visualized on a 1% agarose gel and purified by Exo-SAP
treatment (USBproducts,Affymetyrics,Cleveland,Ohio USA). PCR
products were sequenced using the same primers as the ones used for
amplification. Due to the longer amplicon size of the exon 2 PCR
products a number of samples failed for the analysis of the SNPs in
this region leadingtoa less effective discrimination between the CWD
HLA-A2 subtypes in these samples. This led to ambiguities for some
a l l e l e s .U s i n gt h ep r i m e rs e ta si n d i c a t e da b o v ew ew e r en o ta b l et o
discriminate between HLA-A*02:01 and HLA-A*02:03, leading to a
HLA-A*02:01/02:03 ambiguity. Sequence data were analyzed using
Seqman software (DNA Star, Madison, WI).
Statistical Analysis
Significant differences in HLA-A2 positivity and in phenotype
frequency of HLA-A2 subtypes between the total cHL group and
the control subjects as well as those between EBV+ and EBV2
cHL patients were assessed by Chi-square. Logistic regression
analyses were used to determine the odds ratios and their 95%
confidence intervals. A p-value,0.05 was considered significant. A
multivariate analysis was done by logistic regression analysis using
EBV status as the dependent variable and age (continuous), sex,
diagnosis and HLA-A*02 status as independent variables. The
analyses were performed in PASW Statistics version 18 (SPSS Inc.,
Chicago, Illinois, USA) and Microsoft ExcelH 2003 (Microsoft
corporation, Redmond, Washington, USA).
Supporting Information
Figure S1 Alignment of the HLA-A gene fragments that
are amplified and sequenced to discriminate between
common and well defined HLA-A2 alleles. The five SNPs
that are able to discriminate between the major HLA-A2 subtypes
(IMGT/HLA database, http://www.ebi.ac.uk/imgt/hla/) are
indicated by boxes. (A) Two SNPs located at position 98 and
102 are specific for HLA-A*02:05, A*02:06 and A*02:10. (B)
SNPs located at position 355 and 402 are specific for HLA-
A*02:05 only and one SNP at position 368 can differentiate both
HLA-A*02:07 and A*02:10 from others. Numbers above the
sequences indicate nucleotide positions. Nucleotide sequences
were aligned to the HLA-A*01:01 allele. Dashes indicate identity
with the reference sequence. Supplementary information is
available at Genes and Immunity’s website http://www.nature.
com/gene/index.html.
(DOC)
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